ABPI responds to Party Manifestos

The Association of the British Pharmaceutical Industry (ABPI) has responded to the Labour, Liberal Democrat and Conservative Party Manifestos.

Measuring its response according to analysis of the policies announced in the manifestos under each of the three themes set out in the ABPI’s own manifesto document, ‘Securing the Opportunity for UK Life Sciences by 2022’, the ABPI set out its replies to the pledges.

In response to Labour’s Manifesto, the ABPI said in a statement: “The pharmaceutical industry welcomes the Labour Party’s commitment to ensuring patients get fast access to new medicines through an NHS boosted by increased levels of funding.

“However, as Britain negotiates its departure from the EU, the UK must convince the rest of the world that Britain is open for business. As such, the pharmaceutical industry is concerned that Labour’s headline pledges on taxation – such as increasing Corporation Tax – may have unintended consequences that could undermine the UK’s global competitiveness.” 

In answer to the Lib Dems’ pledges, the ABPI said: “To tackle Britain’s productivity problem, the pharmaceutical industry welcomes the Liberal Democrats’ focus on investing in science and innovation to grow the UK economy and deliver prosperity. However if we’re serious about making the UK the go-to place for R&D, the pharmaceutical industry would like to see a clear vision for how people can benefit from the latest scientific advances in medical research.

“So while the additional £6bn a year for the NHS is an important commitment that is welcomed by industry, we are concerned that the Liberal Democrats’ manifesto plans for healthcare fail to tackle the trend of poor patient access to the latest medical innovations in the UK.”

Responding to the Conservative Manifesto, the ABPI commented: ​”The ABPI welcomes the Conservatives’ approach to tackling UK business productivity and growth through an approach to Industrial Strategy that would help in securing the economy and delivering prosperity. This includes a commitment to grow and maintain our science base, a promise of further investment in R&D, and a new strategy to develop much needed STEM skills. 

“Yet, the strength of the pharmaceutical industry in the UK will also depend on securing the right Brexit deal, and securing an ambitious, world-class healthcare system. To deliver this, the pharmaceutical industry believes the NHS will require a longer-term sustainable funding solution and we will also need to take greater steps to reverse poor UK patient access to medicines and treatments.​”